Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock
NCT ID: NCT02062970
Last Updated: 2019-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
230 participants
INTERVENTIONAL
2014-02-28
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The mechanisms involved on one hand an activation of white blood cells inflammatory system and the vascular inflammatory system; and on the other hand on imbalance in hemostatis characterized by an activation of the coagulation and an inappropriate fibrinolysis leading to a disruption of microcirculation in the context of a disseminated intravascular coagulation (DIVC).
This inflammatory and thrombotic cellular activation is strongly associated with the phenomenon of vesiculation; leading to the production of cellular microparticles (MP) by blood cells and vascular cells.
MP are membranous vesicles, resulting in the reassortment of membrane phospholides in response to an activation of cellular apoptosis. They have been initially described as new actors of hemostatis. Indeed, the expression of phospholipid serine and tissular factor (TF) confer them a procoagulating activity, which increases in patients undergoing septic shock.
The finding of a fibriniolytic activity of the cellular MP suggests the existence of compensating mechanisms with a procoagulating activity. This confers to MP a key-role in the control of the coagulolytic balance.
Our recent researches suggest that endothelial and white blood cells MP produce in vivo plasmin.
They carry into the main circulation a fibrinolytic activity which is partially beyond the physiological inhibitors activity (PAI-1, x 2 antiplasmin). Preliminary findings show that this ability of plasmin generation is important in patients affected with septic shock.
Our hypothesis is that an increase in plasmin generation by MP compensates the risk of occurrence of microthrombosis, modulating therefore the vital prognosis of patients with septic shock.
The coagulolytic balance of MP, which is resulting of their own procoagulating and fibrinolytic activities could claim the status of new pronostic marker relevant in patients with septic shock.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hemodynamic Evaluation Using Microcirculation for Early Treatment of Septic Patients
NCT06910891
Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance
NCT02391792
Membrane Shedding During Septic Shock
NCT01604551
Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock
NCT01149278
Evaluation of the Prognostic Value of Immature Platelet Fraction
NCT07039227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
septic shock patients suffering
blood sample done in a population whom suffer of septic shock
blood draw
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood draw
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant woman
* septic shock since more than 24 hours
* patient hospitalized for cardiac arrest
* immunocompromised patients
* patient in whom the stop of active therapeutic is discuss
* patient treated with an anti-coagulant at therapeutic dose
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mondoloni Loic
Role: STUDY_DIRECTOR
Assistance Publique des Hôpitaux de Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assistance Publique des Hôpitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lacroix R, Judicone C, Souab KH, Bonifay A, Loundou A, Bouriche T, Cointe S, Vallier L, Abdili E, Arnaud L, Robert S, Poncelet P, Grosdidier C, Morange P, Cochery-Nouvellon E, Bouvier S, Gris JC, Lefrant JY, Leone M, Albanese J, Dignat-George F. The Procoagulant and Fibrinolytic Balance of Extracellular Vesicles Predicts Mortality in Septic Shock Patients. J Extracell Vesicles. 2025 Jun;14(6):e70073. doi: 10.1002/jev2.70073.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-36
Identifier Type: OTHER
Identifier Source: secondary_id
2013-A01251-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.